151 related articles for article (PubMed ID: 22515084)
1. Amphotericin B-loaded nanocarriers for topical treatment of cutaneous leishmaniasis: development, characterization, and in vitro skin permeation studies.
Santos CM; de Oliveira RB; Arantes VT; Caldeira LR; de Oliveira MC; Egito ES; Ferreira LA
J Biomed Nanotechnol; 2012 Apr; 8(2):322-9. PubMed ID: 22515084
[TBL] [Abstract][Full Text] [Related]
2. Enhanced stability and permeation potential of nanoemulsion containing sefsol-218 oil for topical delivery of amphotericin B.
Hussain A; Samad A; Singh SK; Ahsan MN; Faruk A; Ahmed FJ
Drug Dev Ind Pharm; 2015 May; 41(5):780-90. PubMed ID: 24654936
[TBL] [Abstract][Full Text] [Related]
3. Nanocarrier-based topical drug delivery for an antifungal drug.
Hussain A; Samad A; Nazish I; Ahmed FJ
Drug Dev Ind Pharm; 2014 Apr; 40(4):527-41. PubMed ID: 23627443
[TBL] [Abstract][Full Text] [Related]
4. Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B.
Frankenburg S; Glick D; Klaus S; Barenholz Y
Antimicrob Agents Chemother; 1998 Dec; 42(12):3092-6. PubMed ID: 9835496
[TBL] [Abstract][Full Text] [Related]
5. Formulation and optimization of nanoemulsion using antifungal lipid and surfactant for accentuated topical delivery of Amphotericin B.
Hussain A; Singh VK; Singh OP; Shafaat K; Kumar S; Ahmad FJ
Drug Deliv; 2016 Oct; 23(8):3101-3110. PubMed ID: 27854145
[TBL] [Abstract][Full Text] [Related]
6. Nanoemulsions loaded with amphotericin B: a new approach for the treatment of leishmaniasis.
Caldeira LR; Fernandes FR; Costa DF; Frézard F; Afonso LC; Ferreira LA
Eur J Pharm Sci; 2015 Apr; 70():125-31. PubMed ID: 25660615
[TBL] [Abstract][Full Text] [Related]
7. Nanoemulsions containing amphotericin b and paromomycin for the treatment of cutaneous leishmaniasis.
Cunha NFC; de Siqueira LBO; Garcia AR; Rodrigues IA; Matos APDS; Júnior ER; Monteiro MSSB
Acta Trop; 2024 Jun; 254():107189. PubMed ID: 38522630
[TBL] [Abstract][Full Text] [Related]
8. Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis.
Riezk A; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
Molecules; 2020 Sep; 25(17):. PubMed ID: 32887341
[TBL] [Abstract][Full Text] [Related]
9. Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation.
Hussain A; Samad A; Singh SK; Ahsan MN; Haque MW; Faruk A; Ahmed FJ
Drug Deliv; 2016; 23(2):642-47. PubMed ID: 25013957
[TBL] [Abstract][Full Text] [Related]
10. Preparation and Characterization of Nanostructured Lipid Carriers for Improved Topical Drug Delivery: Evaluation in Cutaneous Leishmaniasis and Vaginal Candidiasis Animal Models.
Riaz A; Hendricks S; Elbrink K; Guy C; Maes L; Ahmed N; Kiekens F; Khan GM
AAPS PharmSciTech; 2020 Jul; 21(5):185. PubMed ID: 32632542
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis.
Yardley V; Croft SL
Int J Antimicrob Agents; 2000 Feb; 13(4):243-8. PubMed ID: 10755238
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the in vivo leishmanicidal activity of amphotericin B emulgel: An alternative for the treatment of skin leishmaniasis.
Pinheiro IM; Carvalho IP; de Carvalho CE; Brito LM; da Silva AB; Conde Júnior AM; de Carvalho FA; Carvalho AL
Exp Parasitol; 2016 May; 164():49-55. PubMed ID: 26902606
[TBL] [Abstract][Full Text] [Related]
13. Leishmanicidal activity of amphotericin B encapsulated in PLGA-DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice.
de Carvalho RF; Ribeiro IF; Miranda-Vilela AL; de Souza Filho J; Martins OP; Cintra e Silva Dde O; Tedesco AC; Lacava ZG; Báo SN; Sampaio RN
Exp Parasitol; 2013 Oct; 135(2):217-22. PubMed ID: 23891944
[TBL] [Abstract][Full Text] [Related]
14. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp.
Ruiz HK; Serrano DR; Dea-Ayuela MA; Bilbao-Ramos PE; Bolás-Fernández F; Torrado JJ; Molero G
Int J Pharm; 2014 Oct; 473(1-2):148-57. PubMed ID: 24998510
[TBL] [Abstract][Full Text] [Related]
15. Drug delivery systems for the topical treatment of cutaneous leishmaniasis.
Carneiro G; Aguiar MG; Fernandes AP; Ferreira LA
Expert Opin Drug Deliv; 2012 Sep; 9(9):1083-97. PubMed ID: 22724539
[TBL] [Abstract][Full Text] [Related]
16. Topical Amphotericin B solid lipid nanoparticles: Design and development.
Butani D; Yewale C; Misra A
Colloids Surf B Biointerfaces; 2016 Mar; 139():17-24. PubMed ID: 26700229
[TBL] [Abstract][Full Text] [Related]
17. Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro.
Perez AP; Altube MJ; Schilrreff P; Apezteguia G; Celes FS; Zacchino S; de Oliveira CI; Romero EL; Morilla MJ
Colloids Surf B Biointerfaces; 2016 Mar; 139():190-8. PubMed ID: 26709977
[TBL] [Abstract][Full Text] [Related]
18. A new nanoemulsion formulation improves antileishmanial activity and reduces toxicity of amphotericin B.
Santos DCMD; de Souza MLS; Teixeira EM; Alves LL; Vilela JMC; Andrade M; Carvalho MDG; Fernandes AP; Ferreira LAM; Aguiar MMG
J Drug Target; 2018 Apr; 26(4):357-364. PubMed ID: 29041824
[TBL] [Abstract][Full Text] [Related]
19. Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis.
Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Murdan S; Croft SL
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263075
[TBL] [Abstract][Full Text] [Related]
20. Topical amphotericin B for cutaneous leishmaniasis.
Vardy D; Barenholz Y; Cohen R; Zvulunov A; Biton A; Klaus S; Frankenburg S
Arch Dermatol; 1999 Jul; 135(7):856-7. PubMed ID: 10411171
[No Abstract] [Full Text] [Related]
[Next] [New Search]
